person · Reporting owner
GRIFFIN MICHELLE RENEE
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acer Therapeutics Inc.ACER · Entity 108116 | Director | March 14, 2023 | March 16, 2023 |
| Adaptive Biotechnologies CorpADPT · Entity 1126 | Director | June 25, 2026 | June 29, 2026 |
| HTG MOLECULAR DIAGNOSTICS, INCHTGM · Entity 112530 | Director | September 15, 2022 | September 15, 2022 |
| PHASERX, INC.PZRX · Entity 174777 | Director | May 25, 2017 | May 30, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acer Therapeutics Inc.
Report date March 14, 2023 · Filed March 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.67 · Expires 2033-03-14 | Direct | 20,000 |
Reported balance
After 2023-03-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-14 · Grant · Acquired 20,000 · Balance 20,000 F1: The option, which is made as part of the Issuer's 2023 annual compensation cycle, vests and becomes exercisable in full on March 14, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The option, which is made as part of the Issuer's 2023 annual compensation cycle, vests and becomes exercisable in full on March 14, 2024.
Adaptive Biotechnologies Corp
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,625 |
Ending reported balance
After 2026-06-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-25 · Exercise / conversion · Acquired 52,084 · Balance 67,709 F1: The transactions reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2025. Row 2 · 2026-06-25 · Sale · Disposed 52,084 · Balance 15,625 F1: The transactions reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2025. F2: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $20.00 to $20.55, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2029-04-23 | Direct | 0 |
Reported balance
After 2026-06-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-25 · Exercise / conversion · Disposed 52,084 · Balance 0 F1: The transactions reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2025. F3: The option was fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2025.
F2: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $20.00 to $20.55, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3: The option was fully vested and exercisable.
HTG MOLECULAR DIAGNOSTICS, INC
Report date September 15, 2022 · Filed September 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.86 · Expires 2032-09-14 | Direct | 4,000 |
Reported balance
After 2022-09-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-09-15 · Grant · Acquired 4,000 · Balance 4,000 F1: The shares will vest on the earlier of September 15, 2023 or the date of the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares will vest on the earlier of September 15, 2023 or the date of the next annual meeting of stockholders.
PHASERX, INC.
Report date May 25, 2017 · Filed May 30, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.08 · Expires 2027-05-25 | Direct | 14,000 |
Reported balance
After 2017-05-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-25 · Grant · Acquired 14,000 · Balance 14,000 F1: On May 25, 2017, the reporting person was granted an option to purchase shares of common stock. The option vests in 1/12th equal installments on each monthly anniversary of May 25, 2017, and subject to the reporting person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 25, 2017, the reporting person was granted an option to purchase shares of common stock. The option vests in 1/12th equal installments on each monthly anniversary of May 25, 2017, and subject to the reporting person's continued service to the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CHINOOK THERAPEUTICS, INC.
Report date August 11, 2023 · Filed August 11, 2023
Section 16 reporting ended · disclosed 2023-08-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 1
1 source rowRow 1 · 2023-08-11 · Disposition to issuer · Disposed 3,300 · Balance 0 F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.77 · Expires 2030-10-05 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-11 · Disposition to issuer · Disposed 23,522 · Balance 0 F2: This stock option award, which provided for ratable vesting in 36 monthly installments beginning on November 6, 2020, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.81 · Expires 2031-06-03 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-08-11 · Disposition to issuer · Disposed 5,948 · Balance 0 F3: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.88 · Expires 2032-05-25 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-08-11 · Disposition to issuer · Disposed 13,300 · Balance 0 F3: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.
F2: This stock option award, which provided for ratable vesting in 36 monthly installments beginning on November 6, 2020, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F3: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2026 Filed Jun 29, 2026 23:49 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 52,084 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001229765-26-000008 · form4.xml · derivative · entry 3 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,084 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2025. F3 · derivative.exercise_date: The option was fully vested and exercisable. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 23:49 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 52,084 | $20.18 | $1,051,055.12 |
DisclosureSEC source: 0001229765-26-000008 · form4.xml · nonDerivative · entry 2 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,625 F1 · kind: The transactions reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2025. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $20.00 to $20.55, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 23:49 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 52,084 | $7.80 | $406,255.20 |
DisclosureSEC source: 0001229765-26-000008 · form4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2025. Read SEC document |
| March 11, 2026 Filed Mar 14, 2026 01:05 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 15,394 | $13.91 | $214,130.54 |
DisclosureSEC source: 0001229765-26-000006 · form4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,625 F1 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $13.84 to $13.96, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 04, 2026 Filed Mar 7, 2026 00:08 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 15,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001229765-26-000004 · form4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,019 Read SEC document |
| March 03, 2026 Filed Mar 6, 2026 01:05 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 48,044 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001229765-26-000001 · primary_doc.xml · derivative · entry 3 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,044 shares Expires 2034-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2025. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 03, 2026 Filed Mar 6, 2026 01:05 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 48,044 | $15.30 | $735,073.20 |
DisclosureSEC source: 0001229765-26-000001 · primary_doc.xml · nonDerivative · entry 2 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,394 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.11 to $15.54, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 03, 2026 Filed Mar 6, 2026 01:05 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 48,044 | $3.99 | $191,695.56 |
DisclosureSEC source: 0001229765-26-000001 · primary_doc.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2025. Read SEC document |
| March 13, 2025 Filed Mar 17, 2025 23:33 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 36,291 | $7.19 | $260,932.29 |
DisclosureSEC source: 0001062993-25-005644 · form4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,394 F1 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $7.15 to $7.25, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 06, 2025 Filed Mar 7, 2025 00:14 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 15,664 | $7.94 | $124,372.16 |
DisclosureSEC source: 0001062993-25-004800 · form4.xml · nonDerivative · entry 2 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,685 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2024. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $7.64 to $8.21, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 04, 2025 Filed Mar 7, 2025 00:14 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (right to buy) · Derivative | 23,726 | $0.00 Strike: $8.12 | $0.00 |
DisclosureSEC source: 0001062993-25-004800 · form4.xml · derivative · entry 3 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,726 Underlying: Common Stock · 23,726 shares Expires 2035-03-04 F3 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2025, subject to continued service as a director through such vesting dates. Read SEC document |
| March 04, 2025 Filed Mar 7, 2025 00:14 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 15,394 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-004800 · form4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,349 Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 00:43 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (right to buy) · Derivative | 48,044 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001062993-24-005770 · form4.xml · derivative · entry 2 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,044 Underlying: Common Stock · 48,044 shares Expires 2034-03-04 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2024, subject to continued service as a director through such vesting dates. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 00:43 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 31,328 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-005770 · form4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,955 Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:09 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,300 | $26.12 Strike: $13.88 | $347,396.00 |
DisclosureSEC source: 0001209191-23-045422 · doc4.xml · derivative · entry 4 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,300 shares Expires 2032-05-25 F3 · derivative.exercise_date: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:09 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,948 | $23.19 Strike: $16.81 | $137,934.12 |
DisclosureSEC source: 0001209191-23-045422 · doc4.xml · derivative · entry 3 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,948 shares Expires 2031-06-03 F3 · derivative.exercise_date: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:09 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 23,522 | $25.23 Strike: $14.77 | $593,460.06 |
DisclosureSEC source: 0001209191-23-045422 · doc4.xml · derivative · entry 2 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,522 shares Expires 2030-10-05 F2 · derivative.exercise_date: This stock option award, which provided for ratable vesting in 36 monthly installments beginning on November 6, 2020, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:09 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerCommon Stock | 3,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045422 · doc4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. Read SEC document |
| May 26, 2023 Filed May 31, 2023 19:23 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionRestricted Stock Units · Derivative | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033188 · doc4.xml · derivative · entry 2 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer's common stock. F3 · derivative.exercise_date: 100% of the RSUs vested on May 26, 2023, subject to the Reporting Persons continued service to the Issuer on the vesting date. F3 · derivative.expiration_date: 100% of the RSUs vested on May 26, 2023, subject to the Reporting Persons continued service to the Issuer on the vesting date. Read SEC document |
| May 26, 2023 Filed May 31, 2023 19:23 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionCommon Stock | 3,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-033188 · doc4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 21:01 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 2,341 | $8.49 | $19,878.13 |
DisclosureSEC source: 0001062993-23-008033 · form4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,627 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2023. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.41 to $8.55, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 16:37 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001209191-23-019317 · doc4.xml · derivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-03-14 F1 · derivative.exercise_date: The option, which is made as part of the Issuer's 2023 annual compensation cycle, vests and becomes exercisable in full on March 14, 2024. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:06 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (right to buy) · Derivative | 23,329 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001062993-23-006333 · form4.xml · derivative · entry 2 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,329 Underlying: Common Stock · 23,329 shares Expires 2033-03-06 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2023, subject to continued service as a director through such vesting dates. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:06 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 14,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-006333 · form4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,968 Read SEC document |
| September 15, 2022 Filed Sep 15, 2022 18:12 UTC | HTG MOLECULAR DIAGNOSTICS, INC HTGM · Entity 112530 | GrantStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001209191-22-050149 · doc4.xml · derivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2032-09-14 F1 · derivative.exercise_date: The shares will vest on the earlier of September 15, 2023 or the date of the next annual meeting of stockholders. Read SEC document |
| May 26, 2022 Filed May 31, 2022 18:40 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantRestricted Stock Unit · Derivative | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032971 · doc4.xml · derivative · entry 2 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,300 Underlying: Common Stock · 3,300 shares Expires 2023-05-26 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: 100% of the RSUs will vest on May 26, 2023, subject to the Reporting Person's continued service to the Issuer on the vesting date. Read SEC document |
| May 26, 2022 Filed May 31, 2022 18:40 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantStock Option (right to buy) · Derivative | 13,300 | $0.00 Strike: $13.88 | $0.00 |
DisclosureSEC source: 0001209191-22-032971 · doc4.xml · derivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,300 Underlying: Common Stock · 13,300 shares Expires 2032-05-25 F1 · derivative.exercise_date: 100% of the stock option will vest on May 26, 2023, subject to the Reporting Person's continued service to the Issuer on the vesting date. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 16,722 | $0.00 Strike: $14.95 | $0.00 |
DisclosureSEC source: 0001209191-22-005497 · doc4.xml · derivative · entry 2 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,722 Underlying: Common Stock · 16,722 shares Expires 2032-01-26 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 6,689 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005497 · doc4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,193 Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 16:22 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | GrantStock Option (right to buy) · Derivative | 18,500 | $0.00 Strike: $2.21 | $0.00 |
DisclosureSEC source: 0001209191-22-003718 · doc4.xml · derivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2032-01-14 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on January 14, 2023. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,916 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-21-053971 · doc4.xml · derivative · entry 3 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,084 Underlying: Common Stock · 14,916 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 28, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 14,916 | $35.00 | $522,060.00 |
DisclosureSEC source: 0001209191-21-053971 · doc4.xml · nonDerivative · entry 2 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,916 | $7.80 | $116,344.80 |
DisclosureSEC source: 0001209191-21-053971 · doc4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
| August 18, 2021 Filed Aug 19, 2021 17:21 UTC | HTG MOLECULAR DIAGNOSTICS, INC HTGM · Entity 112530 | GrantStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $6.25 | $0.00 |
DisclosureSEC source: 0001209191-21-052589 · doc4.xml · derivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2031-08-17 F1 · derivative.exercise_date: The shares will vest on the earlier of August 18, 2022 or the date of the next annual meeting of stockholders. Read SEC document |
| July 14, 2021 Filed Jul 20, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-21-047303 · doc4.xml · derivative · entry 3 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 2,500 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 28, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| July 14, 2021 Filed Jul 20, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 2,500 | $36.80 | $92,000.00 |
DisclosureSEC source: 0001209191-21-047303 · doc4.xml · nonDerivative · entry 2 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
| July 14, 2021 Filed Jul 20, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 2,500 | $7.80 | $19,500.00 |
DisclosureSEC source: 0001209191-21-047303 · doc4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-21-042289 · doc4.xml · derivative · entry 3 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,500 Underlying: Common Stock · 4,000 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 28, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 4,000 | $40.00 | $160,000.00 |
DisclosureSEC source: 0001209191-21-042289 · doc4.xml · nonDerivative · entry 2 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 4,000 | $7.80 | $31,200.00 |
DisclosureSEC source: 0001209191-21-042289 · doc4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-21-041089 · doc4.xml · derivative · entry 3 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,500 Underlying: Common Stock · 2,500 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 28, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 2,500 | $38.56 | $96,400.00 |
DisclosureSEC source: 0001209191-21-041089 · doc4.xml · nonDerivative · entry 2 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 2,500 | $7.80 | $19,500.00 |
DisclosureSEC source: 0001209191-21-041089 · doc4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
| June 04, 2021 Filed Jun 7, 2021 21:35 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantStock Option (Right to Buy) · Derivative | 5,948 | $0.00 Strike: $16.81 | $0.00 |
DisclosureSEC source: 0001209191-21-038797 · doc4.xml · derivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,948 Underlying: Common Stock · 5,948 shares Expires 2031-06-03 F1 · derivative.exercise_date: The option award will fully vest upon the earlier of 1) the Issuer's next annual stockholder meeting, or 2) June 4, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 18, 2021 Filed May 20, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-21-034235 · doc4.xml · derivative · entry 3 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,000 Underlying: Common Stock · 2,500 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 28, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| May 18, 2021 Filed May 20, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 2,500 | $35.00 | $87,500.00 |
DisclosureSEC source: 0001209191-21-034235 · doc4.xml · nonDerivative · entry 2 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
| May 18, 2021 Filed May 20, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 2,500 | $7.80 | $19,500.00 |
DisclosureSEC source: 0001209191-21-034235 · doc4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
| April 14, 2021 Filed Apr 17, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-21-027123 · doc4.xml · derivative · entry 3 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,500 Underlying: Common Stock · 4,500 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 28, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| April 14, 2021 Filed Apr 17, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 4,500 | $43.41 | $195,345.00 |
DisclosureSEC source: 0001209191-21-027123 · doc4.xml · nonDerivative · entry 2 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
| April 14, 2021 Filed Apr 17, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 4,500 | $7.80 | $35,100.00 |
DisclosureSEC source: 0001209191-21-027123 · doc4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.